Dow Jones
39.118,86 -45,24 (-0,12%) Nasdaq
17.732,60 -126,10 (-0,71%) Nikkei 225
39.687,40 +104,32 (+0,26%) EUR/USD
1,0758 +0,0043 (+0,40%) Bitcoin EUR
58.909,20 +2.421,86 (+4,29%) CMC Crypto 200
1.314,83 +31,00 (+2,41%)
CRBP Sep 2024 20.000 call
| Chiusura precedente | 28,40 |
| Aperto | 28,40 |
| Denaro | 23,60 |
| Domanda | 28,00 |
| Prezzo d'esercizio | 20,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 28,40 - 28,40 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 2 |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
